Alvotech (ALVO)
ALVO Stock Price Chart
Explore Alvotech interactive price chart. Choose custom timeframes to analyze ALVO price movements and trends.
ALVO Company Profile
Discover essential business fundamentals and corporate details for Alvotech (ALVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
16 Jun 2022
Employees
1.01K
Website
https://www.alvotech.comCEO
Robert Wessman
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
ALVO Financial Timeline
Browse a chronological timeline of Alvotech corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is $0.08, while revenue estimate is $119.80M.
Earnings released on 13 Aug 2025
EPS came in at $0.14 surpassing the estimated -$0.26 by +153.85%, while revenue for the quarter reached $173.24M , beating expectations by +11.37%.
Earnings released on 7 May 2025
EPS came in at $0.35 surpassing the estimated -$0.17 by +305.88%, while revenue for the quarter reached $132.77M , beating expectations by +10.17%.
Earnings released on 26 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.39 by +38.46%, while revenue for the quarter reached $151.21M , beating expectations by +54.31%.
Earnings released on 13 Nov 2024
EPS came in at $0.19 surpassing the estimated -$0.06 by +401.59%, while revenue for the quarter reached $489.68M , beating expectations by +476.10%.
Earnings released on 15 Aug 2024
EPS came in at $0.28 surpassing the estimated -$0.28 by +200.00%, while revenue for the quarter reached $198.75M , beating expectations by +136.61%.
Earnings released on 21 May 2024
EPS came in at -$0.89 falling short of the estimated -$0.08 by -972.29%, while revenue for the quarter reached $12.43M .
Earnings released on 20 Mar 2024
EPS came in at -$1.22 falling short of the estimated $0.15 by -913.33%, while revenue for the quarter reached $53.39M , missing expectations by -21.49%.
Earnings released on 28 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.29 by -182.76%, while revenue for the quarter reached $17.79M , missing expectations by -58.63%.
Earnings released on 30 Aug 2023
EPS came in at -$0.43 falling short of the estimated -$0.14 by -207.14%, while revenue for the quarter reached $4.39M , missing expectations by -89.55%.
Earnings released on 19 May 2023
EPS came in at -$0.33 , while revenue for the quarter reached $15.86M .
Earnings released on 1 Mar 2023
EPS came in at -$1.29 , while revenue for the quarter reached $23.86M .
Earnings released on 16 Nov 2022
EPS came in at -$0.04 , while revenue for the quarter reached $19.05M .
Earnings released on 1 Sept 2022
EPS came in at -$0.54 , while revenue for the quarter reached $39.67M .
Earnings released on 16 May 2022
EPS came in at -$0.32 , while revenue for the quarter reached $452.00K .
Earnings released on 30 Mar 2022
EPS came in at $1.28 , while revenue for the quarter reached $34.76M .
Earnings released on 15 Nov 2021
EPS came in at -$0.41 , while revenue for the quarter reached $536.00K .
Earnings released on 16 Aug 2021
EPS came in at -$0.01 , while revenue for the quarter reached $1.18M .
Earnings released on 20 May 2021
EPS came in at $0.23 , while revenue for the quarter reached $1.18M .
Earnings released on 31 Mar 2021
EPS came in at -$0.30 , while revenue for the quarter reached $16.65M .
Earnings released on 30 Sept 2020
EPS came in at -$0.17 , while revenue for the quarter reached $16.65M .
ALVO Stock Performance
Access detailed ALVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.